R.B. Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 04-07-2024
- Paid Up Capital ₹ 0.62 M
as on 04-07-2024
- Company Age 27 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.50 M
as on 04-07-2024
- Revenue -20.60%
(FY 2023)
- Profit -7.59%
(FY 2023)
- Ebitda -13.96%
(FY 2023)
- Net Worth 9.61%
(FY 2023)
- Total Assets 5.86%
(FY 2023)
About R.B. Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.62 M.
The company currently has active open charges totaling ₹9.50 M.
Bulbul Sannigrahi, Animesh Sannigrahi, Anwesha Sannigrahi, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24232WB1997PTC084719
- Company No.
084719
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Jun 1997
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at R.B. Pharma?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bulbul Sannigrahi  | Director | 24-Jun-1997 | Current |
| Animesh Sannigrahi | Director | 24-Jun-1997 | Current |
| Anwesha Sannigrahi | Director | 11-Apr-2018 | Current |
| Anirban Sannigrahi | Director | 11-Apr-2018 | Current |
| Amrita Sannigrahi | Director | 11-Apr-2018 | Current |
| Asoke Sannigrahi | Director | 24-Jun-1997 | Current |
Financial Performance and Corporate Structure Insights of R.B. Pharma.
R.B. Pharma Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 20.6% decrease. The company also saw a slight decrease in profitability, with a 7.59% decrease in profit. The company's net worth moved up by a moderate rise of 9.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of R.B. Pharma?
In 2023, R.B. Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
7 years 2 months Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
United Bank Of India Creation Date: 29 Sep 2009 | ₹6.00 M | Open |
United Bank Of India Creation Date: 29 Mar 2008 | ₹3.50 M | Open |
How Many Employees Work at R.B. Pharma?
Unlock and access historical data on people associated with R.B. Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
As of Mar 17, 2018, R.B. Pharma has raised a total of ₹ 0.93 M, with the most recent deal valued at ₹ 0.12 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
